IFNA2 and COVID-19: Supporting these findings, a similar clinical study administering IFN-α-2b i.n. to patients admitted to hospital with COVID-19 reduced pro-inflammatory cytokine levels and improved the recovery rate compared to treatment with the antiviral agent arbidol hydrochloride [25].